A Gallup poll suggests nearly 8 million fewer people are obese than in 2022 — a drop that coincides with the surging use of ...

Until recently, GLP -1s, a powerful new class of weight-loss drugs, were confined mostly to rich countries. Yet the World ...

GLP-1 receptor agonists show promise in treating various chronic conditions, but potential risks and unanswered questions remain for care of patients with NETs.

The scientists who published the study used gene-editing technology to make the livers of mice produce its own Ozempic-like ...

LOUISVILLE, KY. — A panel representing retail and food processing discussed consumer insights at the recent American Egg Board and United Egg Producers annual joint executive conference in Louisville, ...

The cost of employer-sponsored health insurance rose for the third year in a row in 2025, approaching an average of almost $27,000 for a family plan, according to an annual survey from KFF released ...

Research has suggested the potential of GLP-1 medications for treating substance use disorders, including alcohol, opioids, ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

The U.S. adult obesity rate, calculated as having a BMI of 30 or higher, has gradually declined to 37% in 2025, dropping from ...

The number of people using injectable obesity treatments is increasing rapidly, and it is leading to declines in obesity, ...

GLP-1s hold promise as a potential treatment for alcohol and substance use disorders, according to an expert endocrine ...